药物在头颈部肿瘤治疗中引起铁死亡的作用机制

国际肿瘤学杂志››2022,Vol. 49››Issue (3): 173-176.doi:10.3760/cma.j.cn371439-20210922-00029

药物在头颈部肿瘤治疗中引起铁死亡的作用机制

曾艳¹, 罗盼¹, 王子琪¹, 吴伟莉^1,^2,³()

¹贵州医科大学临床医学院肿瘤学教研室,贵阳 550000
²贵州医科大学附属医院肿瘤科,贵阳 550000
³贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550000

收稿日期:2021-09-22修回日期:2021-10-07出版日期:2022-03-08发布日期:2022-03-22
通讯作者:吴伟莉 E-mail:wwlmhy@163.com
基金资助:
国家自然科学基金(82060555);贵州医科大学国家自然科学基金培育项目(19NSP047)

Mechanism of drug induced ferroptosis in the treatment of head and neck tumors

Zeng Yan¹, Luo Pan¹, Wang Ziqi¹, Wu Weili^1,^2,³()

¹Department of Oncology, School of Clinical Medicine, Guizhou Medical University, Guiyang 550000, China
²Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang 550000
³Department of Head and Neck Oncology, Cancer Hospital Affiliated to Guizhou Medical University, Guiyang 550000, China

Received:2021-09-22Revised:2021-10-07Online:2022-03-08Published:2022-03-22
Contact:Wu Weili E-mail:wwlmhy@163.com
Supported by:
National Natural Science Foundation of China(82060555);Cultivate Project for Natio-nal Natural Science Foundation of China, Guizhou Medical University(19NSP047)

摘要/Abstract

摘要：

铁死亡是一种由脂质活性氧驱动的铁依赖形式的调节性细胞死亡,在肿瘤的发生发展中发挥重要作用。多种临床药物如青蒿素衍生物、伊曲康唑、柳氮磺胺吡啶、葫芦素B、紫杉醇、双硫仑/铜等可通过不同机制诱发头颈部肿瘤铁死亡从而抑制肿瘤生长。对临床常用药物在头颈部肿瘤治疗中诱导铁死亡的调控机制进行研究,可为头颈部肿瘤铁死亡的靶点治疗提供参考。

曾艳, 罗盼, 王子琪, 吴伟莉. 药物在头颈部肿瘤治疗中引起铁死亡的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 173-176.

Zeng Yan, Luo Pan, Wang Ziqi, Wu Weili. Mechanism of drug induced ferroptosis in the treatment of head and neck tumors[J]. Journal of International Oncology, 2022, 49(3): 173-176.

参考文献31

[1]	Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1):92. DOI: 10.1038/s41572-020-00224-3. doi:10.1038/s41572-020-00224-3pmid:33243986
[2]	Stockwell BR, Jiang X, Gu W. Emerging mechanisms and disease relevance of ferroptosis[J]. Trends Cell Biol, 2020, 30(6):478-490. DOI: 10.1016/j.tcb.2020.02.009. doi:S0962-8924(20)30054-4pmid:32413317
[3]	Xie Y, Hou W, Song X, et al. Ferroptosis: process and function[J]. Cell Death Differ, 2016, 23(3):369-379. DOI: 10.1038/cdd.2015.158. doi:10.1038/cdd.2015.158pmid:26794443
[4]	Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer[J]. Cancer Cell, 2019, 35(6):830-849. DOI: 10.1016/j.ccell.2019.04.002. doi:S1535-6108(19)30197-7pmid:31105042
[5]	Alvarez SW, Sviderskiy VO, Terzi EM, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis[J]. Nature, 2017, 551(7682):639-643. DOI: 10.1038/nature24637. doi:10.1038/nature24637
[6]	Seiler A, Schneider M, Förster H, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase depen-dent- and AIF-mediated cell death[J]. Cell Metab, 2008, 8(3):237-248. DOI: 10.1016/j.cmet.2008.07.005. doi:10.1016/j.cmet.2008.07.005
[7]	Efferth T. From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy[J]. Semin Cancer Biol, 2017, 46:65-83. DOI: 10.1016/j.semcancer.2017.02.009. doi:S1044-579X(17)30029-9pmid:28254675
[8]	Lin R, Zhang Z, Chen L, et al. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells[J]. Cancer Lett, 2016, 381(1):165-175. DOI: 10.1016/j.canlet.2016.07.033. doi:10.1016/j.canlet.2016.07.033
[9]	Roh JL, Kim EH, Jang H, et al. Nrf2 inhibition reverses the resis-tance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis[J]. Redox Biol, 2017, 11:254-262. DOI: 10.1016/j.redox.2016.12.010. doi:10.1016/j.redox.2016.12.010
[10]	Zhang W, Bhagwath AS, Ramzan Z, et al. Itraconazole exerts its antitumor effect in esophageal cancer by suppressing the HER2/AKT signaling pathway[J]. Mol Cancer Ther, 2021, 20(10):1904-1915. DOI: 10.1158/1535-7163.MCT-20-0638. doi:10.1158/1535-7163.MCT-20-0638pmid:34376577
[11]	Takahashi S, Karayama M, Takahashi M, et al. Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors[J]. Clin Cancer Res, 2021, 27(21):5771-5780. DOI: 10.1158/1078-0432.CCR-21-1560. doi:10.1158/1078-0432.CCR-21-1560
[12]	Buczacki SJA, Popova S, Biggs E, et al. Itraconazole targets cell cycle heterogeneity in colorectal cancer[J]. J Exp Med, 2018, 215(7):1891-1912. DOI: 10.1084/jem.20171385. doi:10.1084/jem.20171385
[13]	Gerber DE, Putnam WC, Fattah FJ, et al. Concentration-dependent early antivascular and antitumor effects of itraconazole in non-small cell lung cancer[J]. Clin Cancer Res, 2020, 26(22):6017-6027. DOI: 10.1158/1078-0432.CCR-20-1916. doi:10.1158/1078-0432.CCR-20-1916
[14]	Xu Y, Wang Q, Li X, et al. Itraconazole attenuates the stemness of nasopharyngeal carcinoma cells via triggering ferroptosis[J]. Environ Toxicol, 2021, 36(2):257-266. DOI: 10.1002/tox.23031. doi:10.1002/tox.23031
[15]	Zhao B, Li X, Wang Y, et al. Iron-dependent cell death as executioner of cancer stem cells[J]. J Exp Clin Cancer Res, 2018, 37(1):79. DOI: 10.1186/s13046-018-0733-3. doi:10.1186/s13046-018-0733-3
[16]	Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression[J]. Oncogene, 2018, 37(36):5007-5019. DOI: 10.1038/s41388-018-0307-z. doi:10.1038/s41388-018-0307-z
[17]	Shin D, Kim EH, Lee J, et al. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer[J]. Free Radic Biol Med, 2018, 129:454-462. DOI: 10.1016/j.freeradbiomed.2018.10.426. doi:10.1016/j.freeradbiomed.2018.10.426
[18]	Pouillon L, Bossuyt P, Vanderstukken J, et al. Management of patients with inflammatory bowel disease and spondyloarthritis[J]. Expert Rev Clin Pharmacol, 2017, 10(12):1363-1374. DOI: 10.1080/17512433.2017.1377609. doi:10.1080/17512433.2017.1377609
[19]	Gout PW, Buckley AR, Simms CR, et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug[J]. Leukemia, 2001, 15(10):1633-1640. DOI: 10.1038/sj.leu.2402238. doi:10.1038/sj.leu.2402238pmid:11587223
[20]	Kim EH, Shin D, Lee J, et al. CISD2 inhibition overcomes resis-tance to sulfasalazine-induced ferroptotic cell death in head and neck cancer[J]. Cancer Lett, 2018, 432:180-190. DOI: 10.1016/j.canlet.2018.06.018. doi:10.1016/j.canlet.2018.06.018
[21]	Yuan R, Zhao W, Wang QQ, et al. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis[J]. Pharmacol Res, 2021, 170:105748. DOI: 10.1016/j.phrs.2021.105748. doi:10.1016/j.phrs.2021.105748
[22]	Bakar-Ates F, Ozkan E, Sengel-Turk CT. Encapsulation of cucur-bitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage[J]. Int J Pharm, 2020, 586:119565. DOI: 10.1016/j.ijpharm.2020.119565. doi:10.1016/j.ijpharm.2020.119565
[23]	Wang K, Ye H, Zhang X, et al. An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition[J]. Biomaterials, 2020, 257:120224. DOI: 10.1016/j.biomaterials.2020.120224. doi:10.1016/j.biomaterials.2020.120224
[24]	Tao B, Wang D, Yang S, et al. Cucurbitacin B inhibits cell proli-feration by regulating X-inactive specific transcript expression in tongue cancer[J]. Front Oncol, 2021, 11:651648. DOI: 10.3389/fonc.2021.651648. doi:10.3389/fonc.2021.651648
[25]	Huang S, Cao B, Zhang J, et al. Induction of ferroptosis in human nasopharyngeal cancer cells by cucurbitacin B: molecular mechanism and therapeutic potential[J]. Cell Death Dis, 2021, 12(3):237. DOI: 10.1038/s41419-021-03516-y. doi:10.1038/s41419-021-03516-y
[26]	Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression[J]. Nature, 2015, 520(7545):57-62. DOI: 10.1038/nature14344. doi:10.1038/nature14344
[27]	Ou Y, Wang SJ, Li D, et al. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses[J]. Proc Natl Acad Sci U S A, 2016, 113(44):E6806-E6812. DOI: 10.1073/pnas.1607152113. doi:10.1073/pnas.1607152113
[28]	Wen G, Qu XX, Wang D, et al. Recent advances in design, synjournal and bioactivity of paclitaxel-mimics[J]. Fitoterapia, 2016, 110:26-37. DOI: 10.1016/j.fitote.2016.02.010. doi:10.1016/j.fitote.2016.02.010
[29]	Ye J, Jiang X, Dong Z, et al. Low-concentration PTX and RSL3 inhibits tumor cell growth synergistically by inducing ferroptosis in mutant p53 hypopharyngeal squamous carcinoma[J]. Cancer Manag Res, 2019, 11:9783-9792. DOI: 10.2147/CMAR.S217944. doi:10.2147/CMAR.S217944
[30]	McMahon A, Chen W, Li F. Old wine in new bottles: advanced drug delivery systems for disulfiram-based cancer therapy[J]. J Control Release, 2020, 319:352-359. DOI: 10.1016/j.jconrel.2020.01.001. doi:10.1016/j.jconrel.2020.01.001
[31]	Li Y, Chen F, Chen J, et al. Disulfiram/copper induces antitumor activity against both nasopharyngeal cancer cells and cancer-associa-ted fibroblasts through ROS/MAPK and ferroptosis pathways[J]. Cancers (Basel), 2020, 12(1):138. DOI: 10.3390/cancers12010138. doi:10.3390/cancers12010138